herpes-zoster

Documents about herpes-zoster

• Herpes Zoster: Risk Factors, Complications and Special Situations#981624ClinicalTrials.gov
• Herpes Zoster Vaccine for Bone Marrow Transplant Donors#152496ClinicalTrials.gov
• Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age#230473ClinicalTrials.gov
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster#432924ClinicalTrials.gov
• Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine#174963ClinicalTrials.gov
• Phase III Study of ASP2151 in Herpes Zoster Patients#850870ClinicalTrials.gov
• Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand#894291ClinicalTrials.gov
• A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)#195410ClinicalTrials.gov
• Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)#249672ClinicalTrials.gov
• Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections#838095ClinicalTrials.gov
• Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects#245575ClinicalTrials.gov
• Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions#459972ClinicalTrials.gov
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years#162540ClinicalTrials.gov
• The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster#966191ClinicalTrials.gov
• Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older#195386ClinicalTrials.gov
• Rhomboid Intercostal and Subserratus Plane Block Versus Paravertebral Block for Thoracic Herpes Zoster#850507ClinicalTrials.gov
• Shingrix in Renal Transplant Recipients#968056ClinicalTrials.gov
• A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022#383618ClinicalTrials.gov
• Herpes zoster ophthalmicus with prolonged viral shedding following COVID-19 infection#466999ARPHA OAI-PMH Endpoint
• Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.#863701ClinicalTrials.gov
• A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster#894079ClinicalTrials.gov
• A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)#321543ClinicalTrials.gov
• Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation#882539ClinicalTrials.gov
• A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals#314394ClinicalTrials.gov
• Real-World Safety and Herpes Zoster Outcomes After Recombinant Zoster Vaccination in Inflammatory Bowel Disease#408885IRIS
• A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine#154734ClinicalTrials.gov
• Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine#261344ClinicalTrials.gov
• Reduction of Postherpetic Neuralgia in Herpes Zoster#829874ClinicalTrials.gov
• Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage#968508ClinicalTrials.gov
• Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above#903652ClinicalTrials.gov
• Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects#184941ClinicalTrials.gov
• Study on Efficacy of Attenuated Zoster Vaccine, Live#444747ClinicalTrials.gov
• Risk factors and vaccination gaps for herpes zoster in people living with HIV: A multicenter multivariable study#200853Recep Tayyip Erdoğan University Institutional Repository
• A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants#856924ClinicalTrials.gov
• A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults#435777ClinicalTrials.gov
• Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older#848625ClinicalTrials.gov
• A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults#146276ClinicalTrials.gov
• Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above#303579ClinicalTrials.gov
• Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older#394620ClinicalTrials.gov
• A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster#867810ClinicalTrials.gov
• A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster#877522ClinicalTrials.gov
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older#162535ClinicalTrials.gov
• Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older#172373ClinicalTrials.gov
• A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India#208288ClinicalTrials.gov
• Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age#217084ClinicalTrials.gov
• Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds#467612ClinicalTrials.gov
• Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis#865846ClinicalTrials.gov
• A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine#363655ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects#398192ClinicalTrials.gov
• VZV PCR Sampling Validation Study#857121ClinicalTrials.gov